BioCentury
ARTICLE | Management Tracks

Mistras, Martin join Viatris

Plus: Nassim Usman at the helm at Totus as it raises $66M series B round, and updates from Tourmaline, HKEX, CIRM, CorMedix and RiverVest

December 16, 2023 12:29 AM UTC

Viatris Inc. (NASDAQ:VTRS) hired Theodora “Doretta” Mistras to succeed CFO Sanjeev Narula, effective March 1, 2024. Mistras was managing director, healthcare investment banking at Citigroup Global Markets and Goldman Sachs & Co. LLC. Viatris also hired Philippe Martin as chief R&D officer, effective immediately. Martin was chief development & operations at BioAtla Inc. (NASDAQ:BCAB). 

Nassim Usman became president and CEO of Totus Medicines Inc., which also announced a $66 million series B round led by DCVC Bio. Founding CEO Neil Dhawan became head of R&D while remaining CSO. Usman was president, CEO, and board member at Catalyst Biosciences Inc. Totus is developing TOS-358, a PI3Kα inhibitor for genetically defined cancer. North Pond Ventures, Camford Capital and the Regents of the University of Minnesota participated in the series B. ...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article